George Clinical Applauded by Frost & Sullivan for Its Competitive Differentiation and Leadership in Strategy Execution in the Asia Pacific region

George Clinical cares for its employees, enables business continuity, and builds on its expertise, giving it a competitive industry advantage.

SAN ANTONIO, May 4, 2023 /PRNewswire/ — Frost & Sullivan studied the contract research organization industry and, based on its findings, recognizes George Clinical with the 2023 Asia-Pacific Competitive Strategy Leadership Award. George Clinical is a global CRO with world class expertise in Kidney research, Oncology and Neurology and remains fully committed to growing their strong presence in Asia-Pacific which is where the company has its roots. It operates on the central tenet that its success depends on customer satisfaction, so it provides a human touch to its projects. A sustainable skilled workforce inherently ensures quality outcomes for clients and patients. High employee retention rates also result in new hires through current employee referrals and, more importantly, lower project downtime risks, reducing potential costs from replacing and training new hires.  Unlike larger contract research organizations (CROs), the company promotes a healthy work-life balance for its employees where they do not operate like machines when executing a trial.

George Clinical upholds its agility and responsiveness towards clients with nearly 500 employees, making it more flexible, adaptable, and faster than competitors with more employees. The company stands out in the industry as it works hard to deliver high-quality scientific services while identifying solutions for big biopharma. It meets with clients to assess their needs and develop tailored solutions with roadmaps for seamless execution, establishing ongoing trust with customers for long-lasting relationships. It links the science of an academic research organization (ARO) with a CRO’s global operational processes to meet standard operating procedures.

Azza Fazar, Frost & Sullivan best practices research analyst, observed, “George Clinical combines its connections with AROs and scientific expertise to find suitable sites and investigator networks, a unique competitive differentiator. The company facilitates faster patient-centric recruitment for its clients by bringing the best of both worlds.”

George Clinical works closely with customers during the pre- and post-purchase journey, offering support and guidance to achieve clinical trial excellence within specific therapeutic areas. It excels in creating brand awareness fueled by its exceptional operational strategies and customer-centric design, thus, achieving more leads. Its sterling reputation and customer-centric framework have led to its coveted preferred partner status. Additionally, it established a central monitoring team in India for cost-effectiveness, enabling it to monitor and prove the effectiveness of clinical trial trends across countries. With its long-standing GKPTN network access to a range of chronic kidney disease patients, client-focused oncology trial strategies and geographies, and best practice implementation, it outpaces competitors to lead the APAC CRO sector.

“George Clinical provides a human touch to its projects, ensuring quality outcomes for clients and patients. It develops and implements its growth strategies with customers in mind, solidifying its reputation in the sector,” noted Umesh Lal, Frost & Sullivan industry analyst. With its strong overall performance, George Clinical earns Frost & Sullivan’s 2023 APAC Competitive Leadership Award in the contract research organization industry.

Each year, Frost & Sullivan presents this award to a company that has developed a pioneering technology that enhances current products and enables the development of new products and applications. The award recognizes the high sector acceptance potential of the recipient’s technology.

Frost & Sullivan Best Practices awards recognize companies in various regional and global sectors for demonstrating outstanding achievement and superior performance in leadership, technological innovation, customer service, and strategic product development. Industry experts compare sector participants and measure performance through in-depth interviews, analyses, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan
For six decades, Frost & Sullivan has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Contact:
Tarini Singh
P: +91-9953764546
E: [email protected]

About George Clinical
George Clinical is a leading global clinical research organization founded in Asia-Pacific driven by scientific expertise and operational excellence. With over 20 years of experience and more than 450 people managing 39 geographical locations throughout the Asia-Pacific region, USA, and Europe, George Clinical provides the full range of clinical trial services to biopharmaceutical, medical device, and diagnostic customers, for all trial phases, registration, and post-marketing trials.    
Website: https://www.georgeclinical.com 
LinkedIn: https://www.linkedin.com/company/george-clinical-pty-ltd 
Twitter: https://twitter.com/george_clinical 
Facebook: https://www.facebook.com/georgeclinical 
WeChat: https://mp.weixin.qq.com/.

For more information, contact:
Matthew Reabold
Head, US Business Development
T +1-760-645-0496
E [email protected] 
W georgeclinical.com | georgeinstitute.org

 

SOURCE Frost & Sullivan

第三季酒店業僱員數量升兩成 人資需求增加

澳門統計暨普查局資料顯示,今年第3季末酒店業的全職僱員按年增加21.7%至53,802名。

英皇娛樂酒店中期淨溢利1210萬港元

英皇娛樂酒店有限公司公佈中期業績公告,截至2023年9月30日止6個月期間轉虧為盈,錄得淨溢利1210萬港元。

美國今年“黑五”購物周近幾年“最便宜”

新華社北京11月29日電 美國上周迎來“黑色星期五”購物周。據路透社28日報道,今年“黑五”購物周堪稱數年來“最便宜”,大批消費者受零售商的大力促銷吸引,多番比價、“精明”購物。

澳門首十月酒店入住率超八成

澳門統計暨普查局資料顯示,今年首十月澳門酒店業客房平均入住率同比上升43個百分點至80.9%,住客增加1.6倍至1,104.1萬人次。

【法律解碼】新《金融體系法律制度》:需要了解的重要事項

新《金融體系法律制度》:需要了解的重要事項

【息息相關】REITs 時代

在澳門證券基金行業協會舉辦的論壇上,業內人士和專家一致認為,澳門在發展不動產信託基金(REITs)市場方面擁有優勢,可以進一步推動金融業發展,加快經濟多元化進程。

普華永道:2024年中國經濟增速有望超過今年

新華社北京11月26日電 普華永道會計師事務所中國資深經濟學家趙廣彬日前表示,隨著政府採取的一系列政策措施發力顯效以及私營部門投資增長,2024年中國經濟增速有望超過今年。

國際貿易中心執行主任:數字互聯互通將成為未來貿易關鍵因素之一

新華社日內瓦11月26日電(記者陳斌傑)聯合國和世界貿易組織的合設機構國際貿易中心執行主任帕梅拉·科克-漢密爾頓日前在瑞士日內瓦接受新華社記者書面採訪時表示,數字互聯互通將成為未來貿易中的關鍵因素之一。

【息息相關】“澳門居民的保險、保障嚴重不足”

作為新成立的保誠保險澳門分行總經理,馬竹豪看到澳門人壽保險業務的巨大潛力。他表示,這家擁有175年歷史的英國跨國企業將配合特區的多元化步伐,著眼於橫琴,為澳門市場注入創新元素。

協議生效!巴以停火4天

新華社加沙/耶路撒冷11月24日電 當地時間24日上午7時(北京時間13時),巴勒斯坦伊斯蘭抵抗運動(哈馬斯)和以色列在加沙地帶的臨時停火協議生效。雙方將休戰4天。

相關文章

10月入境旅客按月升二成

澳門統計暨普查局資料顯示,今年10月入境旅客按年增3.8倍至2,757,308人次,與9月相比上升19.8%。

【特刊】“‘一帶一路’已作出了改變,且將迎來更多變化”

澳門大學社會科學學院政府與公共行政學系副教授Francisco Leandro是“一帶一路”研究領域的權威專家。在接受採訪時,他預計該倡議將進一步改進,包括更看重“綠色絲綢之路”維度。

永利澳門第三季EBITDAR增至2.55億美元

永利澳門公佈,今年第三季度經調整後的物業EBITDAR為2.549億美元,環比增長3.57%。

美高梅中國第三季淨收入較疫前增10%

美高梅中國宣佈其第三季度淨收入為8.13億美元(約合65億澳門元),較2019年第三季度增加10%。

新濠第三季營運收入升至9470萬美元,淨虧損收窄

新濠博亞娛樂有限公司公佈,今年第三季度的營運收入為9470萬美元(約合7.6億澳門元),較上一季錄得的6430萬美元環比增長47%。

澳門企業家代表團赴滬參加進博會

澳門貿易投資促進局組織一行近50人的澳門企業家代表團4日赴滬參加第六屆中國國際進口博覽會,這是澳門連續第6年組織 本地企業參與進博會。 澳門特區行政長官賀一誠受邀於4日至5日赴上海,出席第六屆進博會開幕式及相關活動。